DNA tests can be interesting, but medical decisions need stronger evidence.

Short answer

Direct-to-consumer genetic tests may report ancestry, traits, wellness information, or some health-related variants. FDA and NIH sources emphasize that evidence varies, companies may test different variants, and a negative result does not always mean no risk.

Start here

RET and MEN2 pathways

Use these routing guides first when a RET or medullary thyroid cancer report raises more than one follow-up question.

Genetic counseling

Genetic counseling is most useful when a result could change screening, treatment, pregnancy planning, or family communication. Read the genetic counselor guide.

Pharmacogenomics

Pharmacogenomics testing can help with selected medication questions, but genes are only one part of drug response. Read the pharmacogenomics testing guide.

Carrier screening

Carrier screening is most useful before or during pregnancy planning, especially when partner testing and residual risk are explained clearly. Read the carrier screening guide.

Raw DNA uploads

Raw DNA upload sites can generate new reports, but privacy, clinical confirmation, and family implications matter before sharing genetic data. Read the raw DNA upload privacy guide.

FDA authorization

FDA authorization is specific to a test and claim; it does not mean every possible variant is covered or that medical action never needs confirmation. Read the FDA-authorized genetic tests guide.

Polygenic risk scores

Polygenic risk scores combine many variants into a statistical risk estimate, but validation, ancestry, and clinical actionability matter. Read the polygenic risk score guide.

Whole genome sequencing

Whole genome sequencing can produce a large amount of DNA data, but interpretation, confirmation, reanalysis, and privacy controls determine its usefulness. Read the whole genome sequencing reports guide.

Hereditary cancer risk

Hereditary cancer genetic testing is most useful when family history, personal history, or tumor testing suggests a syndrome and counseling can explain medical action. Read the hereditary cancer testing guide.

Tumor versus inherited testing

Tumor genomic testing helps guide cancer treatment, while inherited genetic testing explains germline risk for a person and sometimes relatives. Read the tumor versus inherited testing guide.

Hereditary heart disease testing

Genetic testing for hereditary heart disease is strongest when family history, cholesterol patterns, cardiomyopathy, arrhythmia, or sudden-death concerns point to a focused question. Read the hereditary heart disease genetic testing guide.

Newborn screening versus genetic testing

Newborn screening checks selected treatable conditions soon after birth and is not the same as broad genome sequencing. Read the newborn screening guide.

MTHFR testing claims

MTHFR testing is often overmarketed; common variants should not be turned into broad wellness conclusions. Read the MTHFR testing claims guide.

Prenatal screening versus diagnostic testing

Prenatal screening estimates risk, while CVS and amniocentesis can answer diagnostic questions. Read the prenatal genetic testing guide.

HLA-B27 testing

HLA-B27 can support a spondyloarthritis workup when symptoms fit, but it is not a standalone arthritis diagnosis. Read the HLA-B27 test guide.

Celiac HLA typing

Celiac HLA typing is most useful for ruling out celiac disease when key DQ2 or DQ8 patterns are absent. Read the celiac HLA typing guide.

APOE testing claims

APOE testing can report Alzheimer's risk context, but it does not diagnose disease or make future health certain. Read the APOE testing claims guide.

CYP2C19 pharmacogenetic testing

CYP2C19 results are most useful when tied to a specific medication decision such as clopidogrel or selected PPIs and antidepressants. Read the CYP2C19 pharmacogenetic guide.

Factor V Leiden testing

Factor V Leiden testing is most useful when clot history, family history, pregnancy context, or thrombophilia questions make the result clinically actionable. Read the Factor V Leiden testing guide.

BRCA testing versus broad cancer panels

BRCA1/BRCA2 testing and broader hereditary cancer panels can answer different questions, and variant uncertainty makes genetic counseling especially important. Read the BRCA versus broad panels guide.

BRCA VUS result interpretation

A BRCA variant of uncertain significance should be handled as an uncertain result, with care guided by personal and family history while the variant remains unclassified. Read the BRCA VUS interpretation guide.

PALB2 genetic testing result interpretation

PALB2 results should be sorted by pathogenic versus VUS wording, germline versus tumor-only context, breast cancer risk, pancreatic-risk questions, and family testing. Read the PALB2 result interpretation guide.

CHEK2 genetic testing result interpretation

CHEK2 result interpretation depends on variant classification, family history, germline context, and whether breast, colon, prostate, or other risk claims are supported for the exact result. Read the CHEK2 result interpretation guide.

ATM genetic testing result interpretation

ATM result interpretation depends on variant classification, germline versus tumor-only context, breast cancer risk, pancreatic and prostate questions, radiation concerns, and family-testing implications. Read the ATM result interpretation guide.

Lynch syndrome genetic testing

Lynch syndrome testing can involve tumor screening, germline testing, and family cascade testing when colorectal, endometrial, or related cancer history fits. Read the Lynch syndrome genetic testing guide.

Familial hypercholesterolemia testing

Familial hypercholesterolemia genetic testing can confirm inherited LDL risk and guide family screening, but cholesterol levels and treatment context still matter. Read the FH genetic testing guide.

FH clinical criteria versus genetic testing

Familial hypercholesterolemia is often suspected from LDL levels and family history before genetic testing is considered, and a negative DNA result does not erase clinical risk. Read the FH clinical criteria versus genetic testing guide.

Hereditary hemochromatosis testing

Hereditary hemochromatosis testing is most useful when iron studies, family history, or symptoms raise the question of inherited iron overload. Read the hereditary hemochromatosis genetic testing guide.

Alpha-1 antitrypsin deficiency testing

Alpha-1 antitrypsin deficiency testing may combine a protein level, phenotype testing, and SERPINA1 genetics when lung, liver, or family history fits. Read the alpha-1 antitrypsin testing guide.

G6PD testing

G6PD testing often starts with enzyme activity because the clinical question is whether red blood cells are vulnerable to hemolysis after certain triggers. Read the G6PD test guide.

Hemoglobin electrophoresis

Hemoglobin electrophoresis helps identify inherited hemoglobin patterns such as sickle trait, sickle cell disease, and some thalassemia patterns. Read the hemoglobin electrophoresis guide.

Long QT syndrome testing

Long QT syndrome genetic testing can clarify inherited arrhythmia risk when ECG findings, symptoms, or family history make the question clinically important. Read the long QT genetic testing guide.

Marfan syndrome testing

Marfan syndrome genetic testing is most useful when FBN1 results are interpreted with aortic imaging, eye findings, skeletal features, and family history. Read the Marfan syndrome genetic testing guide.

HHT genetic testing

HHT genetic testing can clarify inherited AVM and bleeding risk when clinical features or family history point to hereditary hemorrhagic telangiectasia. Read the HHT genetic testing guide.

Ehlers-Danlos genetic testing

Ehlers-Danlos genetic testing can identify many rarer EDS types, but hypermobile EDS is usually a clinical diagnosis rather than a simple DNA result. Read the EDS genetic testing guide.

Hereditary thrombophilia testing

Hereditary thrombophilia testing is most useful when a result changes clot prevention, treatment duration, pregnancy planning, or family testing. Read the thrombophilia testing guide.

Hereditary cardiomyopathy genetic testing

Hereditary cardiomyopathy genetic testing can clarify inherited heart-muscle risk when it is paired with ECGs, imaging, family history, and counseling. Read the cardiomyopathy genetic testing guide.

Hereditary kidney disease genetic testing

Hereditary kidney disease genetic testing is most useful when early CKD, hearing or eye findings, family history, or biopsy clues suggest an inherited cause. Read the hereditary kidney disease genetic testing guide.

Hereditary arrhythmia panel testing

Hereditary arrhythmia panels can help when ECG findings, fainting, exercise-triggered events, or sudden-death family history suggest an inherited rhythm condition. Read the hereditary arrhythmia panel guide.

Familial thoracic aortic aneurysm and dissection

Familial TAAD genetic testing is most useful when aortic imaging, young-onset aneurysm or dissection, syndromic clues, or family history can guide surveillance. Read the familial aortic aneurysm genetic testing guide.

APOE genetic testing

APOE testing can estimate Alzheimer risk but cannot diagnose or predict dementia by itself, so pre-test planning matters. Read the APOE genetic testing guide.

Hereditary pancreatitis genetic testing

Hereditary pancreatitis panels are most useful after recurrent, young-onset, familial, or unexplained pancreatitis. Read the hereditary pancreatitis genetic testing guide.

HLA-B27 blood test

HLA-B27 can support a spondyloarthritis or uveitis workup when symptoms fit, but it is not a standalone diagnosis or prediction. Read the HLA-B27 blood test guide.

MTHFR genetic testing claims

MTHFR variants are common and often over-marketed for clots, pregnancy loss, supplements, and detox claims. Read the MTHFR genetic testing claims guide.

HLA celiac genetic testing

HLA-DQ2 and HLA-DQ8 testing is most useful for ruling out celiac disease in selected situations, especially when the diagnosis is uncertain or gluten is already gone; a positive result is susceptibility, not diagnosis. Read the HLA celiac genetic testing guide.

Factor V Leiden testing

Factor V Leiden testing can clarify inherited clot-risk context when the result will change decisions about clots, hormones, pregnancy, surgery, or family testing. Read the Factor V Leiden testing guide.

Prothrombin G20210A testing

Prothrombin G20210A testing looks for an F2 variant linked with venous clot risk and is most useful when a result changes a real decision. Read the prothrombin G20210A testing guide.

Protein C, protein S, and antithrombin testing

Protein C, protein S, and antithrombin testing can clarify inherited or acquired thrombophilia patterns, but timing and anticoagulant effects matter. Read the protein C, protein S, and antithrombin testing guide.

Antiphospholipid syndrome antibody testing

Antiphospholipid syndrome antibody testing is an acquired clot-risk workup that usually depends on lupus anticoagulant, anticardiolipin, and beta-2 glycoprotein I patterns over time. Read the antiphospholipid syndrome antibody testing guide.

JAK2 testing for unexplained clots

JAK2 testing can matter when unexplained or unusual-site clots come with high platelets, high hematocrit, or other CBC clues suggesting a myeloproliferative neoplasm. Read the JAK2 testing for unexplained clots guide.

CALR and MPL testing for MPNs

CALR and MPL testing can help when persistent thrombocytosis or marrow-stress clues still suggest an MPN after JAK2 and reactive causes are reviewed. Read the CALR and MPL testing guide.

BCR-ABL1 testing for CML

BCR-ABL1 testing looks for the Philadelphia chromosome fusion that is central to chronic myeloid leukemia diagnosis and monitoring. Read the BCR-ABL1 testing for CML guide.

KIT mutation testing for mast cell disorders

KIT mutation testing can support systemic mastocytosis workups when tryptase, symptoms, pathology, and specialist review fit. Read the KIT mutation testing guide.

PNH flow cytometry testing

PNH flow cytometry looks for missing GPI-linked markers on blood cells when hemolysis, low counts, or unusual clots raise concern. Read the PNH flow cytometry testing guide.

DDX41 genetic testing for inherited myeloid risk

DDX41 testing can matter when adult-onset cytopenias, MDS, AML, or donor selection raises an inherited myeloid-risk question. Read the DDX41 genetic testing guide.

TP53 testing in blood cancer workups

TP53 testing needs careful separation between tumor sequencing and inherited Li-Fraumeni risk. Read the TP53 testing guide.

RUNX1 genetic testing

RUNX1 testing can matter when inherited platelet dysfunction, bleeding history, MDS, AML, or donor selection raise familial platelet disorder concerns. Read the RUNX1 genetic testing guide.

GATA2 deficiency genetic testing

GATA2 testing connects cytopenias, immunodeficiency, HPV-related disease, lymphedema, MDS/AML risk, and family donor decisions. Read the GATA2 deficiency genetic testing guide.

SAMD9 and SAMD9L genetic testing

SAMD9 and SAMD9L testing can matter when marrow failure, monosomy 7, pediatric MDS, MIRAGE, ataxia-pancytopenia, or donor selection raises inherited-risk concerns. Read the SAMD9 and SAMD9L genetic testing guide.

ETV6 genetic testing

ETV6 testing can clarify inherited thrombocytopenia and leukemia predisposition when low platelets, bleeding, and family history fit. Read the ETV6 genetic testing guide.

ANKRD26 genetic testing

ANKRD26 testing can explain inherited thrombocytopenia when low platelets, family history, and myeloid-risk concerns fit. Read the ANKRD26 genetic testing guide.

MECOM genetic testing

MECOM testing can matter in rare inherited marrow-failure patterns with thrombocytopenia, cytopenias, congenital clues, and transplant planning. Read the MECOM genetic testing guide.

RASopathy genetic testing

RASopathy panels are used when Noonan spectrum or related RAS/MAPK pathway clues make a focused genetics question plausible. Read the RASopathy genetic testing guide.

Telomere biology disorder genetic testing

Telomere biology disorder testing combines telomere length and genetics when marrow failure, pulmonary fibrosis, liver disease, or family donor questions fit. Read the telomere biology disorder genetic testing guide.

PTEN hamartoma tumor syndrome genetic testing

PTEN testing can clarify Cowden syndrome and related PTEN hamartoma tumor syndrome questions when macrocephaly, hamartomas, cancer patterns, neurodevelopmental features, or family history fit. Read the PTEN hamartoma tumor syndrome genetic testing guide.

VHL genetic testing

VHL genetic testing helps confirm von Hippel-Lindau syndrome and coordinate surveillance when hemangioblastomas, kidney cancer, pheochromocytoma, pancreatic lesions, or family history fit. Read the VHL genetic testing guide.

MEN1 genetic testing

MEN1 genetic testing can clarify multiple endocrine neoplasia type 1 when parathyroid, pituitary, pancreatic neuroendocrine tumor, family history, or younger-age endocrine tumor clues fit. Read the MEN1 genetic testing guide.

SDHx paraganglioma and pheochromocytoma genetic testing

SDHx testing helps evaluate hereditary paraganglioma and pheochromocytoma syndromes, where the specific gene can change surveillance, parent-of-origin counseling, and family testing. Read the SDHx paraganglioma and pheochromocytoma genetic testing guide.

RET MEN2 genetic testing

RET testing is used when multiple endocrine neoplasia type 2, medullary thyroid cancer, pheochromocytoma, or family history points to a hereditary endocrine tumor syndrome. Read the RET MEN2 genetic testing guide.

NF1 genetic testing for tumor predisposition

NF1 testing can support neurofibromatosis type 1 diagnosis in uncertain cases, clarify mosaic risk, and help frame tumor surveillance questions. Read the NF1 genetic testing guide.

TSC1/TSC2 genetic testing

TSC1 and TSC2 testing can confirm tuberous sclerosis complex, guide family follow-up, and frame mosaicism questions when clinical signs remain strong. Read the TSC1/TSC2 genetic testing guide.

PTCH1 genetic testing

PTCH1 testing is most useful when basal cell cancers, jaw cysts, family history, or other features point toward Gorlin syndrome. Read the PTCH1 genetic testing guide.

BAP1 tumor predisposition genetic testing

BAP1 testing is most useful when melanoma, mesothelioma, kidney cancer, characteristic skin tumors, or family history point toward a hereditary BAP1 pattern. Read the BAP1 tumor predisposition genetic testing guide.

DICER1 syndrome genetic testing

DICER1 testing can guide surveillance and family testing when childhood lung tumors, thyroid findings, ovarian tumors, cystic nephroma, or family history fit. Read the DICER1 syndrome genetic testing guide.

SMARCA4 rhabdoid tumor predisposition genetic testing

SMARCA4 testing is a focused hereditary tumor-risk question when SCCOHT, rhabdoid tumors, tumor testing, or family history points toward a germline result that could affect relatives. Read the SMARCA4 rhabdoid tumor predisposition guide.

FH fumarate hydratase tumor predisposition genetic testing

FH testing can clarify HLRCC risk when kidney cancer patterns, leiomyomas, tumor-only clues, VUS results, or family history make kidney surveillance and family testing relevant. Read the FH tumor predisposition genetic testing guide.

MAX hereditary paraganglioma genetic testing

MAX testing is a focused hereditary PPGL question when pheochromocytoma, paraganglioma, family history, young age, bilateral tumors, or tumor testing makes germline risk relevant. Read the MAX hereditary paraganglioma genetic testing guide.

TMEM127 genetic testing

TMEM127 testing can clarify inherited pheochromocytoma and paraganglioma risk when tumor pattern, family history, or a panel result points toward hereditary surveillance and family follow-up. Read the TMEM127 genetic testing guide.

EPAS1 paraganglioma genetic testing

EPAS1 testing is a specialized HIF2A-related PPGL question where polycythemia, somatostatinoma, tumor-only findings, and mosaicism can affect interpretation. Read the EPAS1 paraganglioma genetic testing guide.

SDHA paraganglioma genetic testing

SDHA testing belongs in broader SDHx evaluation when paraganglioma, pheochromocytoma, SDH-deficient tumors, or family history make surveillance and cascade testing relevant. Read the SDHA paraganglioma genetic testing guide.

VHL vs SDHx paraganglioma genetic testing

VHL and SDHx findings can both appear in PPGL workups, but tumor pattern, organ surveillance, metastatic-risk questions, and family counseling differ. Read the VHL vs SDHx paraganglioma genetic testing guide.

Paraganglioma tumor testing vs germline testing

Tumor testing can explain tumor biology, while germline testing asks whether a paraganglioma result is inherited and relevant to relatives. Read the paraganglioma tumor testing vs germline testing guide.

RET vs VHL pheochromocytoma genetic testing

RET and VHL can both involve pheochromocytoma, but MEN2 thyroid-risk management and VHL multi-organ surveillance lead to different follow-up plans. Read the RET vs VHL pheochromocytoma genetic testing guide.

NF1 pheochromocytoma genetic testing

NF1 pheochromocytoma questions connect neurofibromatosis type 1 features, blood pressure spells, metanephrines, tumor testing, and whether a result is germline or tumor-only. Read the NF1 pheochromocytoma genetic testing guide.

MEN2A vs MEN2B genetic testing

MEN2A and MEN2B are both RET-related syndromes, but variant type, medullary thyroid cancer timing, pheochromocytoma risk, parathyroid findings, and childhood follow-up differ. Read the MEN2A vs MEN2B genetic testing guide.

Mosaic NF1 genetic testing

Mosaic NF1 can be missed by routine blood testing when the variant is not present in blood at detectable levels, so sample choice and clinical pattern matter. Read the mosaic NF1 genetic testing guide.

RET variant of uncertain significance interpretation

A RET VUS is not a confirmed MEN2 result, so it should be interpreted with clinical context, lab classification details, family history, and reclassification follow-up. Read the RET VUS interpretation guide.

Negative RET testing with medullary thyroid cancer

Negative germline RET testing can lower inherited MEN2 concern, but medullary thyroid cancer follow-up may still involve clinical context and separate tumor testing. Read the negative RET testing with MTC guide.

RET tumor testing vs germline testing

RET tumor testing can guide cancer treatment, while germline RET testing addresses inherited MEN2 risk and relatives. Read the RET tumor versus germline testing guide.

Medullary thyroid cancer genetic counseling questions

Medullary thyroid cancer counseling should clarify RET test type, the exact variant, family cascade testing, calcitonin, pheochromocytoma screening, and follow-up timing. Read the medullary thyroid cancer counseling questions guide.

MEN2 family variant testing

MEN2 family variant testing asks whether relatives carry the known RET variant, whether the result is a true negative or a VUS, and what that means for children and cascade testing. Read the MEN2 family variant testing guide.

MEN2 family variant testing

MEN2 family variant testing usually asks whether relatives carry a known RET variant, not whether a tumor has a somatic biomarker. Read the MEN2 family variant testing guide.

RET prenatal and childhood testing questions

RET testing in children can be time-sensitive when a family variant changes MEN2 surveillance or preventive thyroid planning. Read the RET prenatal and childhood testing questions guide.

Positive RET test next steps

A positive RET result should be sorted by sample type, exact variant, germline versus tumor context, and who is coordinating family follow-up. Read the positive RET test next steps guide.

MEN2 surveillance after positive RET testing

MEN2 surveillance after a positive RET result is variant-specific and may include thyroid, adrenal, parathyroid, and family-testing planning. Read the MEN2 surveillance after positive RET testing guide.

RET V804M variant interpretation

RET V804M is often discussed as a moderate-risk MEN2A or familial medullary thyroid cancer variant, and should not be interpreted like codon 918 MEN2B. Read the RET V804M variant interpretation guide.

RET codon 918 MEN2B questions

RET codon 918, especially M918T, is a high-stakes MEN2B question where sample type, childhood timing, and specialist coordination matter. Read the RET codon 918 MEN2B questions guide.

RET codon 634 MEN2A questions

RET codon 634 results should be tied to the exact C634 variant, germline versus tumor context, MEN2A care, and family testing. Read the RET codon 634 MEN2A questions guide.

RET risk category interpretation

RET risk categories are useful only when anchored to the exact variant, sample type, age, calcitonin context, and specialist plan. Read the RET risk category interpretation guide.

RET codon 609, 611, 618, and 620 questions

RET codons 609, 611, 618, and 620 need exact variant, sample type, risk category, family history, and MEN2 specialist context. Read the RET codon 609/611/618/620 guide.

RET negative family variant testing interpretation

A negative RET result can be a true negative or an uninformative negative depending on whether the exact family variant was targeted. Read the RET negative family variant guide.

RET C609Y and C618R report questions

RET C609Y and C618R reports should be read by exact notation, sample type, variant classification, and family context. Read the RET C609Y and C618R report guide.

RET cascade testing for children questions

RET cascade testing for children should target the known family variant and be coordinated with genetics and pediatric endocrine care. Read the RET cascade testing for children guide.

RET calcitonin follow-up after positive genetic testing

RET calcitonin follow-up should be interpreted inside a MEN2-aware plan tied to the exact variant, age, thyroid context, and specialist follow-up. Read the RET calcitonin follow-up guide.

RET family letter questions

A RET family letter should give relatives enough precise information to seek targeted cascade testing without exposing unnecessary private detail. Read the RET family letter questions guide.

RET de novo variant questions

A de novo RET variant can still affect children and family counseling, so parent testing, mosaicism, and exact variant classification matter. Read the RET de novo variant questions guide.

RET VUS family testing questions

A RET VUS should not usually be treated like a known pathogenic family variant; family testing needs a clear genetics purpose. Read the RET VUS family testing guide.

RET mosaicism questions

RET mosaicism questions depend on sample type, allele fraction, de novo context, parent testing, and genetic counseling. Read the RET mosaicism questions guide.

RET tumor-only vs germline follow-up

RET tumor-only results and germline results answer different questions; sample type decides whether relatives need targeted testing. Read the RET tumor-only vs germline guide.

RET allele fraction questions

RET allele fraction can mean different things in blood, saliva, tumor-only, or paired tumor-normal testing, so sample type and variant classification matter. Read the RET allele fraction questions guide.

RET paired tumor-normal testing questions

Paired tumor-normal testing can help separate a RET cancer-treatment clue from an inherited MEN2 family-risk question. Read the RET paired tumor-normal testing guide.

RET normal comparator sample questions

The normal comparator sample in paired RET testing determines what the tumor result is compared against and whether germline follow-up is still needed. Read the RET normal comparator sample guide.

RET saliva vs blood germline testing

RET germline testing may use blood, saliva, cheek cells, or another accepted specimen depending on the lab and clinical context. Read the RET saliva vs blood germline testing guide.

RET result follow-up roadmap

A RET result follow-up roadmap helps route tumor-only findings, paired tumor-normal reports, germline results, mosaicism questions, VUS results, and family testing to the right next step. Read the RET result follow-up roadmap.

RET codon and variant comparison guide

RET codon and variant names can help readers route M918T, codon 634, V804M, codon-group, VUS, and risk-category questions to the right follow-up guide. Read the RET codon and variant comparison guide.

MEN2 family testing and surveillance roadmap

MEN2 follow-up should separate targeted family variant testing from surveillance planning for people who carry a germline RET variant. Read the MEN2 family testing and surveillance roadmap.

Medullary thyroid cancer RET result routing

Medullary thyroid cancer RET result routing separates negative germline, VUS, tumor-only, paired tumor-normal, positive germline, and family-testing paths. Read the medullary thyroid cancer RET result routing guide.

Questions before buying

• Is the test reviewed or authorized by FDA for the claim being marketed?
• Does the report explain analytical validity, clinical validity, and limits in plain language?
• Will a medical result require confirmatory clinical testing before any action?
• Can you access a genetic counselor or qualified clinician for high-impact findings?
• What happens to your sample, raw data, and family-related information?

Best use

For most consumers, DNA results are best treated as a conversation starter, not a diagnosis. Strong pages in this category should help readers decide when curiosity is enough and when a healthcare professional should be involved.